ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Bulk and single-cell transcriptome analyses combined with molecular simulations identify ferritinophagy as a key target for resveratrol in osteoarthritis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiology of osteoarthritis (OA), a common degenerative joint disease, is complicated. The significance of autophagy irregularities and iron metabolism issues in OA has garnered a lot of interest in recent years, with "Ferritinophagy" mediated by NCOA4 acting as a crucial link between the two and potentially a novel therapeutic target. The purpose of this research is to determine whether resveratrol, a naturally occurring substance, protects cartilage via controlling the ferritinophagy network. Using differential analysis, weighted gene co-expression network analysis, and other machine learning methods, this study combined transcriptome data from several omics studies and screened OA core ferritinophagy-related genes. Use molecular docking and molecular dynamics simulations to assess resveratrol's binding mechanism and stability to core targets. The CCK-8 technique was employed in vitro to assess cell survival and identify the ideal resveratrol intervention concentration in an inflammatory model of human articular chondrocytes caused by IL-1β. Using Western blot (WB) to determine the expression of 8 key proteins including NCOA4, GPX4, and LC3. Transmission electron microscopy is used to observe the mitochondrial ultrastructure. NCOA4 protein location and expression were verified using immunofluorescence. Bioinformatics analysis successfully screened key genes such as DDIT4, CTSB, BNIP3, CDKN1A, and NCOA4. Molecular docking and molecular dynamics simulations demonstrate that resveratrol can stably bind to core proteins such as BNIP3 and NCOA4. Resveratrol has been shown in vitro to dramatically increase cell survival and reverse the aberrant expression of important ferritinophagy proteins brought on by IL-1β, upregulating GPX4 and CDKN1A and downregulating NCOA4, LC3-II/I, and BNIP3. The results of transmission electron microscopy demonstrated that resveratrol successfully reduced aberrant autophagosome aggregation and mitochondrial damage. Resveratrol can considerably reduce the unusually high expression of NCOA4, as further demonstrated by immunofluorescence. This study reveals the molecular mechanism by which resveratrol inhibits NCOA4-mediated ferroptophagy, thereby regulating downstream autophagy and ferroptosis processes, and alleviating chondrocyte damage in OA. This provides a new perspective for elucidating the cartilage protective effect of resveratrol and lays a solid theoretical and experimental foundation for developing OA treatment strategies targeting ferritinophagy.
Indexed as
Identifiers
41902854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.